Soligenix, Inc. (NASDAQ:SNGX) Short Interest Update

Soligenix, Inc. (NASDAQ:SNGX) was the recipient of a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 47,100 shares, a drop of 64.9% from the October 15th total of 134,300 shares. Approximately 2.1% of the company’s shares are short sold. Based on an average daily volume of 135,700 shares, the days-to-cover ratio is currently 0.3 days.

Soligenix Trading Down 3.8 %

NASDAQ:SNGX traded down $0.14 during mid-day trading on Friday, hitting $3.54. The company had a trading volume of 14,221 shares, compared to its average volume of 840,590. Soligenix has a fifty-two week low of $1.83 and a fifty-two week high of $32.00. The business’s fifty day moving average is $3.76 and its two-hundred day moving average is $4.36.

Hedge Funds Weigh In On Soligenix

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SNGX. OLD National Bancorp IN bought a new stake in shares of Soligenix in the second quarter worth $26,000. Armistice Capital LLC acquired a new position in shares of Soligenix during the 2nd quarter worth about $206,000. Finally, Stephens Inc. AR bought a new position in shares of Soligenix in the 3rd quarter valued at about $184,000. 3.60% of the stock is owned by institutional investors and hedge funds.

About Soligenix

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.